Lunsumio mosunetuzumab

Drug Class

Bispecific CD20-directed CD3 T-cell engager

Mechanism

Dual-targets CD20 on B-cells and CD3 on T-cells, directing T-cells to execute immune-mediated cytolysis of malignant B-cells.

Approved Indication

Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

What This Means For Patients

Lunsumio is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2022) — Sources
• EMA — Approved (2022) — Sources
• NMPA — Approved (2024) — Sources

Pivotal Clinical Evidence

• GO29781 — Budde et al., Lancet Oncol 2022 (NCT02500407) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761274s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/lunsumio
• https://www.nmpa.gov.cn/